Abstract
This Phase III clinical study will assess the efficacy of BMN 270 defined as FVIII activity,
during weeks 49-52 following intravenous infusion of BMN 270 and assess the impact of BMN 270
on usage of exogenous FVIII replacement therapy and the number of bleeding episodes from week
5 to last visit by data cutoff.
